Echo Therapeutics, Inc. announced that it is initiating a multi-center clinical trial of its Symphony CGM System to support a CE Mark Technical File for marketing approval in Europe. The Company expects to enroll patients over the coming weeks and announce the results of the study in the third quarter of 2013. The clinical study is designed to evaluate the safety and efficacy of the Symphony CGM System in a hospital setting.

Glucose data will be collected from thirty-two critically ill patients at four U.S. medical institutions. The Symphony CGM System glucose readings will be paired with reference blood glucose measurements taken from a YSI 2300 STAT Plus Glucose Analyzer.